Asthma biomarkers in the age of biologics

Allergy, Asthma & Clinical Immunology

Harold Kim, Anne K. Ellis, David Fischer, Mary Noseworthy, Ron Olivenstein, Kenneth R. Chapman and Jason Lee

Allergy, Asthma & Clinical Immunology 2017, 13:48 | Published on: 17 November 2017

Abstract

The heterogeneous nature of asthma has been understood for decades, but the precise categorization of asthma has taken on new clinical importance in the era of specific biologic therapy. The simple categories of allergic and non-allergic asthma have given way to more precise phenotypes that hint at underlying biologic mechanisms of variable airflow limitation and airways inflammation. Understanding these mechanisms is of particular importance for the approximately 10% of patients with severe asthma. Biomarkers that aid in phenotyping allow physicians to “personalize” treatment with targeted biologic agents. Unfortunately, testing for these biomarkers is not routine in patients whose asthma is refractory to standard therapy. Scientific advances in the recognition of sensitive and specific biomarkers are steadily outpacing the clinical availability of reliable and non-invasive assessment methods designed for the prompt and specific diagnosis, classification, treatment, and monitoring of severe asthma patients. This article provides a practical overview of current biomarkers and testing methods for prompt, effective management of patients with severe asthma that is refractory to standard therapy.

Full Text | PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: @worldallergy: '#EAACI2018 Understanding phenotypes and endotypes in… https://t.co/WcFkKLobbc, see more https://t.co/CpGiFuOOYd
2hreplyretweetfavorite
Interasma Top story: EAACI on Twitter: "Announcing #EAACI2018 #SisterSocietySymposium SSS… https://t.co/Wic8jRgFE8, see more https://t.co/CpGiFuOOYd
6hreplyretweetfavorite
Interasma Top story: Graham Roberts on Twitter: "Severe asthma plenary #EAACI2018 - no me… https://t.co/ssW67QWKyG, see more https://t.co/CpGiFuOOYd
18hreplyretweetfavorite
Interasma RT @worldallergy: #EAACI2018 Understanding phenotypes and endotypes in severe #asthma https://t.co/MMyACUQd5c
19hreplyretweetfavorite
Interasma RT @worldallergy: #EAACI2018 Interesting Presentation: Understanding phenotypes and endotypes in severe #asthma, Eugene Bleecker https://t.…
19hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma